Checking bone calcium balance in dialysis children taking cinacalcet
Studies calcium levels in blood and urine of dialysis children with high parathyroid hormone.
Plain-language title generated from the registry record
Registry title: Calcium Isotope Ratios to Assess Calcium Bone Balance in Dialysis Children Receiving Cinacalcet
Key facts
- Where
- Bordeaux, Bron, Montpellier, Nice, Paris, and Strasbourg, FranceSee the 7 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 17 years old?
Source: NCT07007338, who can take part
Where in France
- Service de Pédiatrie CHU de BordeauxBordeaux, FranceTaking people
- Hôpital Femme Mère EnfantBron, FranceTaking people
- Service de pédiatrie multidisciplinaire CHU de MontpellierMontpellier, FranceTaking people
- Unité de néphrologie pédiatrique, Hôpital Archet 2, CHU de NiceNice, FranceTaking people
- Service de Néphrologie - Transplantation - Hémodialyse pédiatrique Hôpital Robert DebréParis, FranceTaking people
- Service de Néphrologie pédiatrique Hôpital Necker Enfants MaladesParis, FranceTaking people
- Service de pédiatrie 1 CHU HautepierreStrasbourg, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospices Civils de Lyon
- Trial code
- NCT07007338
- Record updated
- 22 May 2026
- Original description
Managing bone and mineral disorders associated with chronic kidney disease (CKD-MBD) in children is a complex task. Controlling parathyroid hormone (PTH) levels involves adjusting calcium intake, managing hyperphosphatemia, intensive dialysis, and considering specific therapies like active vitamin D analogues and cinacalcet.Read full original descriptionShow less
Calcium Isotope Ratios to Assess Calcium Bone Balance in Dialysis Children Receiving Cinacalcet - The Cin-Ca Study
Managing bone and mineral disorders associated with chronic kidney disease (CKD-MBD) in children is a complex task. Controlling parathyroid hormone (PTH) levels involves adjusting calcium intake, managing hyperphosphatemia, intensive dialysis, and considering specific therapies like active vitamin D analogues and cinacalcet.
Cinacalcet, authorized in Europe since 2017 for children over 3 undergoing dialysis with secondary hyperparathyroidism (SHPT), has shown efficacy in reducing PTH levels. The 2019 guidelines call for its use with caution particularly to avoid hypocalcemia, in children with severe hyperparathyroidism despite optimized conventional treatments.
In adults, cinacalcet has been found to reduce serum PTH, calcium, and phosphate levels, decrease the risk of vascular calcification, and have a positive effect on bone formation. This suggests that cinacalcet may slow the progression of cardiovascular calcifications.
Additionally, Professor Shroff has introduced a non-invasive method for assessing bone calcium status by analyzing stable calcium isotope ratios in blood. This method would allow to determine whether a treatment such as cinacalcet has a positive influence on bone calcium balance, a key element in the management of CKD-MBD.
Inclusion: Children from 3 to 17 years of age; On maintenance dialysis : hemodialysis, hemodiafiltration, peritoneal dialysis; Patient who begin treatment with cinacalcet based on the 2019 European guidelines and at the discretion of the treating physician; With normal QTc interval on electrocardiogram; With total serum calcium >2.40 mmol/L; With heamoglobin > 8g/dl; Non - opposition from parents/legal guardians.
Exclusion: Patients who received cinacalcet with 3 months prior inclusion; Persons under psychiatric care; Children < 12 kg; Persons deprived of their liberty by a judicial or administrative decision; Persons admitted to a health or social institution for purposes other than research; Persons not affiliated to a social security scheme or beneficiaries of a similar scheme; Persons participating in other interventional research with an exclusion period still in progress at pre-inclusion.